newsfilter
← Latest News
GlobeNewswire·

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second